Share Email Print
cover

Proceedings Paper

Photofrin photodynamic therapy for malignant brain tumors
Author(s): Paul J. Muller; Brian C. Wilson; Lothar D. Lilge; Victor X.D. Yang; Fred W. Hetzel; Qun Chen; Tim Fullagar; Robert Fenstermaker; Robert Selker; Judith Abrams
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

In a phase II trial we treated more than 100 patients with malignant brain tumors with 2-mg/kg Photofrin iv. and intraoperative cavitary PDT. We concluded that PDT was safe in patients with newly diagnosed or recurrent supratentorial malignant gliomas. Regression analysis showed that pathology, performance grade and light dose were significantly related to survival time. We identified a prolongation of survival in selected patients when an adequate light dose was used. The surgical mortality rate was less than 3%. We have initiated two randomized prospective trials - the first, to determine if the addition of PDT to standard therapy [surgery, radiation and/or chemotherapy] prolongs the survival of patients with newly diagnosed malignant astrocytic tumors; and the second, to determine whether high light dose PDT [120 J/cm2] is superior to low light dose PDT [40 J/cm2] in patients with recurrent malignant astrocytic tumors. In the first 20 months of these clinical studies, 90 patients have been recruited. There were 52 in the recurrent study and 37 in the newly diagnosed study. 64% of the tumors were glioblastoma and 23% malignant astrocytoma or malignant mixed glioma. In the trial of newly diagnosed tumors 17 were randomized to surgery with a mean age of 58 ! 2.9 [sem] and 20 to surgery plus PDT with a mean age of 54 ! 2.5. In recurrent glioma trial 26 were randomized to low light dose PDT [mean age 48.1 ! 2.7] and 26 to high light dose [age 52 ! 2.7]. An update of our phase 2 data and a description of brain tumor PDT techniques is presented below. The clinical studies are supported in part by grant CA 43892 awarded by DHHS/NIH/NCI.

Paper Details

Date Published: 9 April 2001
PDF: 12 pages
Proc. SPIE 4248, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy X, (9 April 2001); doi: 10.1117/12.424454
Show Author Affiliations
Paul J. Muller, St. Michael's Hospital/Univ. of Toronto (Canada) and Princess Margaret Hospital/Univ. Of (Canada)
Brian C. Wilson, St. Michael's Hospital/Univ. of Toronto (Canada) and Princess Margaret Hospital/Univ. Of (Canada)
Lothar D. Lilge, St. Michael's Hospital/Univ. of Toronto (Canada) and Princess Margaret Hospital/Univ. Of (Canada)
Victor X.D. Yang, St. Michael's Hospital/Univ. of Toronto (Canada) and Princess Margaret Hospital/Univ. Of (Canada)
Fred W. Hetzel, Swedish Medical Ctr. (United States)
Qun Chen, Swedish Medical Ctr. (United States)
Tim Fullagar, Swedish Medical Ctr. (United States)
Robert Fenstermaker, Roswell Park Cancer Institute (United States)
Robert Selker, Penn West Hospital (United States)
Judith Abrams, Koromos Cancer Ctr. (United States)


Published in SPIE Proceedings Vol. 4248:
Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy X
Thomas J. Dougherty, Editor(s)

© SPIE. Terms of Use
Back to Top